Sarcopenia in chronic kidney disease: Focus on advanced glycation end products as mediators and markers of oxidative stress

Research output: Contribution to journalArticlepeer-review

Abstract

Sarcopenia is common in chronic kidney disease (CKD), and it is independently associated with morbidity and mortality. Advanced glycation end products (AGE) are mainly known as aging products. In CKD, AGE accumulate due to increased production and reduced kidney excretion. The imbalance between oxidant/antioxidant capacities in CKD patients is one of the main factors leading to AGE synthesis. AGE can, in turn, promote CKD progression and CKD-related complications by increasing reactive oxygen species generation, inducing inflammation, and promoting fibrosis. All these derangements can further increase AGE and uremic toxin accumulation and promote loss of muscle mass and function. Since the link between AGE and sarcopenia in CKD is far from being fully understood, we revised hereby the data supporting the potential contribution of AGE as mediators of oxidative stress in the pathogenesis of sarcopenia. Understanding how AGE and oxidative stress impact the onset of sarcopenia in CKD may help to identify new potential markers of disease progression and/or therapeutic targets.

Original languageEnglish
Article number405
JournalBiomedicines
Volume9
Issue number4
DOIs
Publication statusPublished - Apr 2021

Keywords

  • Advanced glycation end products (AGE)
  • Chronic kidney disease
  • Oxidative stress
  • Sarcopenia

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Sarcopenia in chronic kidney disease: Focus on advanced glycation end products as mediators and markers of oxidative stress'. Together they form a unique fingerprint.

Cite this